If we can ignore the sorry state of public companies for a moment, let’s talk about the more encouraging news about private companies’ fundraising records in 2002. A review by Genome Technology’s online sister publication GenomeWeb.com found that pure-play genomic tool and technology companies reported raising about $102.7 million in private-equity cash since January, down only slightly from the $115 million that similar companies reported pocketing during the same eight-month period last year.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.